Xanthopsia (Medication‑Induced)

What is Xanthopsia (Medication Induced)?

Xanthopsia is a visual disturbance in which objects appear yellow‑tinted or the entire visual field takes on a golden hue. The condition is usually temporary and results from the effect of certain drugs on the retina, optic nerve, or visual processing centers in the brain. When the term “medication‑induced” is added, it indicates that the yellowing is not due to an underlying eye disease but is a side‑effect of one or more systemic or topical agents.

Patients often describe the sensation as looking through a “yellow filter” or seeing “everything in sepia.” The alteration can be subtle (a faint warmth) or striking (bright lemon‑colored vision). Because color perception is essential for daily tasks such as reading traffic lights, cooking, or recognizing skin changes, xanthopsia can be unsettling and may interfere with safety‑critical activities.

Most medication‑related cases resolve after the offending drug is reduced, discontinued, or the dose is adjusted. However, persistent or worsening symptoms warrant prompt evaluation to rule out irreversible retinal toxicity.

Common Causes

The following medications and drug classes are most frequently linked to xanthopsia. Note that not everyone who takes these drugs will experience the symptom; risk is influenced by dose, treatment duration, individual metabolism, and pre‑existing eye conditions.

• Digitalis (digoxin, ouabain) – Classic cause; interferes with retinal photoreceptor ion channels.
• Quinine and related antimalarials (chloroquine, hydroxychloroquine) – Can cause retinal pigment changes that manifest as yellow‑tinted vision.

Other drugs known to precipitate xanthopsia

• Topical ophthalmic anesthetics (e.g., tetracaine) – Transient effect after eye procedures.
• Phenothiazines (e.g., chlorpromazine, thioridazine) – Antipsychotics that may alter color perception.
• Isotretinoin (Accutane) – High‑dose retinoids can cause ocular dryness and color shifts.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – Rarely reported visual color changes.
• Vitamin A toxicity – Excess retinol accumulates in retinal pigment epithelium.
• Certain antibiotics (e.g., tetracyclines, especially doxycycline) – Can cause photosensitivity and subtle hue changes.
• Beta‑blocker eye drops (e.g., timolol) – Occasionally reported in glaucoma patients.
• Thyroid hormone replacement (levothyroxine) overdose – Rare metabolic effect on retinal cells.

Associated Symptoms

Because xanthopsia is a symptom rather than a disease, it often co‑exists with other visual or systemic signs related to the causative medication.

• Blurred or reduced visual acuity
• Photophobia (light sensitivity)
• Glare or halos around lights, especially at night
• Dry eyes or gritty sensation (common with topical anesthetics)
• Color discrimination deficits (difficulty distinguishing reds from greens)
• Headache or eye strain after prolonged screen use
• Systemic side‑effects of the drug (e.g., digoxin toxicity: nausea, vomiting, palpitations)
• In cases of retinal toxicity, visual field defects (central scotomas) may appear.

When to See a Doctor

While occasional, mild color distortion may resolve on its own, the following scenarios require prompt medical attention:

• Sudden onset of yellow‑tinted vision, especially if it interferes with daily activities.
• Vision that does not improve after stopping or reducing the suspected medication for 24–48 hours.
• Concurrent symptoms such as flashing lights, new “floaters,” or loss of visual field.
• Systemic signs of drug toxicity (e.g., cardiac arrhythmia with digoxin, skin rash with antibiotics).
• History of pre‑existing eye disease (macular degeneration, glaucoma) that could be worsened by medication.
• Pregnancy or breastfeeding while taking any of the listed drugs.

Diagnosis

Diagnosing medication‑induced xanthopsia involves a systematic approach to confirm the visual change, rule out other ocular pathologies, and identify the offending drug.

Clinical Evaluation

1. History taking – Detailed medication list (including over‑the‑counter, supplements, eye drops), dosage, duration, and timing of visual changes.
2. Symptom characterization – Onset, intensity, triggers, and associated systemic symptoms.
3. Physical eye examination – Visual acuity testing, color vision tests (Ishihara plates, Farnsworth‑Munsell 100 Hue Test), pupillary assessment.

Diagnostic Tests

• Fundus photography & optical coherence tomography (OCT) – Detects retinal pigment epithelium changes, especially with digoxin or hydroxychloroquine.
• Electroretinography (ERG) – Measures retinal electrical responses; useful for confirming drug‑related retinal dysfunction.
• Visual field testing – Identifies scotomas that may accompany toxicity.
• Blood work – Drug serum levels (e.g., digoxin), liver/kidney function, vitamin A levels, complete metabolic panel.
• Medication review by a pharmacist or clinical toxicologist – To assess drug interactions or dosing errors.

Differential Diagnosis

Conditions that can mimic xanthopsia must be excluded, including:

• Age‑related macular degeneration (especially the “drusen” stage)
• Cataracts (especially nuclear sclerosis)
• Retinal or optic nerve inflammation (uveitis, optic neuritis)
• Neurological disorders affecting visual pathways (e.g., migraine aura, stroke)

Treatment Options

Management focuses on eliminating the offending agent, supporting retinal health, and addressing any residual visual disturbance.

Medication Adjustment

• Discontinue or substitute the drug – Done under a physician’s supervision. For example, switching from digoxin to an alternative heart‑failure medication.
• Dose reduction – If the medication is essential, lowering the dose may lessen toxicity.
• Therapeutic drug monitoring – Adjust doses based on serum levels (e.g., digoxin levels <0.8 ng/mL for most patients).

Supportive Eye Care

• Artificial tears for dryness caused by topical anesthetics.
• Protective sunglasses with UV filter to reduce photophobia.
• Low‑vision aids (colored filters, tinted lenses) while symptoms resolve.

Pharmacologic Interventions

• For hydroxychloroquine toxicity, early cessation is key; no specific antidote exists.
• If vitamin A toxicity is identified, cessation of supplements and a low‑retinol diet are recommended.

Rehabilitation

• Color‑vision training with an occupational therapist if persistent deficits remain.
• Patient education on safe driving practices (e.g., avoiding night driving until vision normalizes).

Prevention Tips

Many cases of medication‑induced xanthopsia are avoidable with careful prescribing and monitoring.

• Medication review – Before starting a new drug, discuss eye‑related side effects with your prescriber.
• Use the lowest effective dose – Particularly for drugs known for retinal toxicity (digoxin, hydroxychloroquine).
• Regular ophthalmic screening – Baseline and annual eye exams for patients on long‑term hydroxychloroquine or high‑dose vitamin A.
• Adhere to monitoring guidelines – Follow FDA, CDC, or specialty society recommendations for serum drug level checks.
• Avoid self‑medication – Never use over‑the‑counter eye drops or supplements without consulting a healthcare professional.
• Report visual changes early – Prompt communication with your clinician can prevent permanent damage.
• Stay hydrated and maintain good overall health to support retinal metabolism.

Emergency Warning Signs

Key Take‑aways

Xanthopsia caused by medication is usually reversible but can herald serious drug toxicity or irreversible retinal injury if not addressed promptly. Understanding which drugs are high‑risk, monitoring visual changes, and maintaining regular eye examinations are essential strategies for patients and clinicians alike. When in doubt, early evaluation by an ophthalmologist or a prescribing specialist can safeguard vision and overall health.

References:

• Mayo Clinic. “Digoxin Side Effects.” mayoclinic.org (accessed 2024).
• National Institutes of Health (NIH). “Hydroxychloroquine Retinopathy.” ncbi.nlm.nih.gov (2023).
• Cleveland Clinic. “Medication‑Induced Vision Changes.” clevelandclinic.org (2024).
• World Health Organization. “Guidelines for Monitoring Drug Toxicity.” who.int (2022).
• American Academy of Ophthalmology. “Retinal Toxicity from Systemic Medications.” aao.org (2023).